Stake Purchase • Software

Dominari Holdings Invests In Databricks

On May 12, 2022, Dominari Holdings invested in software company Databricks

Investment Context
  • This is Dominari Holdings’ 1st transaction in the Software sector.
  • This is Dominari Holdings’ 4th transaction in the United States.
  • This is Dominari Holdings’ 1st transaction in California.

Explore All 259 Stake Purchase Software Deals - Search the Database Free


Investment Summary

Date May 12, 2022
Target Databricks
Sector Software
Investor(s) Dominari Holdings
Deal Type Stake Purchase

Target Company

Databricks

San Francisco, California, United States
Databricks is an open-source community that helps organizations make all their data ready for analytics, empowers data science and data-driven decisions across the organization, and rapidly adopts machine learning to outpace the competition. By providing data teams with the ability to process massive amounts of data in the Cloud and power AI with that data, Databricks helps organizations innovate faster and tackle challenges like treating chronic disease through faster drug discovery, improving energy efficiency, and protecting financial markets. Databricks was founded in 2013 and is based in San Francisco, California.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investor Overview 1

Investor

Dominari Holdings

New York, New York, United States

Category Company
Founded 1967
Sector Information Technology
Employees29
Revenue 18M USD (2024)
DESCRIPTION

Dominari Holdings is a scientific research company that offers a diversified commercialization platform for protected technologies. Dominari Holdings was founded and incorporated in 1967 and is based in New York, New York.


Deal Context for Investor #
Overall 4 of 4
Sector: Software 1 of 1
Type: Stake Purchase 1 of 1
State: California 1 of 1
Country: United States 4 of 4
Year: 2022 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-11 CBM Biopharma

United States

CBM Biopharma LLC is a privately held pharmaceutical company with a team of drug development scientists provides numerous cancer treatment, including acute myeloid leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and pancreatic cancer.

Buy -